Glenmark receives tentative approval for Fulvestrant Inj

Pharma major Glenmark was granted tentative USFDA approval for Fulvestrant Injection, 250 mg/5 ml. The shares of the company experienced volatility on an intraday basis. 

The United States Food and Drug Administration (USFDA) has granted a tentative approval to Glenmark for Fulvestrant Injection, 250 mg/5 ml (50 mg/ml), a generic version of FASLODEX 1 Injection, 250 mg/5 ml (50 mg/ml), of AstraZeneca Pharmaceuticals.  According to IQVIA sales data, the FASLODEX  Injection, 250 mg/5 ml (50 mg/ml) achieved annual sales of approximately US$533.3 million for the 12 month period ending December 2018 in the US market. 

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). 

On Thursday, t he shares of the company opened at Rs. 647.50 per share as against its previous close of Rs. 640.75 per share on BSE. At 14:24 hours, the stock was trading at Rs. 641.35 per share, up by 0.09 per cent. Its intraday high was Rs. 647.50 and intraday low was Rs. 634.05. Its 52-week high was Rs. 711.55 and 52-week low was Rs. 483.60 per share on the BSE. Meanwhile, the BSE Sensex was at 37,093.26, up by 0.32 per cent.